|18th September 2020||Global Strategic Fund, L.P. Ven Bio||2,829,123||Conversion of derivative||$0.00|
|18th September 2020||Global Strategic Fund, L.P. Ven Bio||230,000||Open or private purchase||$13.00||$2,990,000.00|
|7th August 2020||Llc Fmr||356,674||Other acquisition or disposition||$0.00|
|15th June 2020||Abid Ansari||8,783||Exercise of derivative||$1.20||$10,539.60|
|15th May 2020||Abid Ansari||8,783||Exercise of derivative||$1.20||$10,539.60|
|15th May 2020||Abid Ansari||878||Exercise of derivative||$1.18||$1,036.04|
|14th April 2020||Derek Jantz||4,392||Exercise of derivative||$1.18||$5,182.56|
|10th February 2020||Llc Fmr||2,189,820||Conversion of derivative||$0.00|
|10th February 2020||Llc Fmr||66,369||Conversion of derivative||$0.00|
|10th February 2020||Llc Fmr||4,715,723||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Precision BioSciences, Inc. engages in the development of genome editing technologies. The company operates through the Therapeutics and Food segments.